

ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC)

A Study of MTIG7192A in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Trial Status

Active, not recruiting

Trial Runs In

6 Countries

Trial Identifier

NCT03563716 2018-000280-81
GO40290

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in chemotherapy-naïve patients with locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), excluding patients with a sensitizing EGFR mutation or ALK translocation.

Genentech, Inc.

Sponsor

Phase 2

Phase

NCT03563716 2018-000280-81 GO40290

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>= 18 Years

Healthy Volunteers

No